IOVA vs REAX
IOVA: Iovance is a pioneer in tumor infiltrating lymphocyte (TIL) cell therapy, offering the first one-time, individualized T cell treatment for advanced solid tumor cancers. REAX: A technology-driven, cloud-based residential real estate brokerage that recently expanded its scale and services through the acquisition of RE/MAX.
Side-by-side fundamentals
| Metric | IOVA | REAX | Edge |
|---|---|---|---|
| Price as of 2026-10-26 close | $13.78 | $15.13 | |
| Market cap as of 2026-07-29 (share count; price 2026-10-26) | $6.2B | n/a | |
| Net margin FY2025, SEC XBRL | -148.4% | -0.4% | REAX higher |
| Gross margin FY2025, SEC XBRL | n/a | +8.4% | |
| Operating margin FY2025, SEC XBRL | -153.1% | -0.5% | REAX higher |
| ROE FY2025, SEC XBRL | -56.0% | -15.7% | REAX higher |
| ROA FY2025, SEC XBRL | -42.8% | -6.4% | REAX higher |
| Debt / equity as of the 2025-12-31 annual report (the quarterly report does not tag consolidated debt) | 0.00 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +60.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +1388.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.54 | 1.09 | |
| 1-year return as of 2026-10-26 close | +512.4% | +287.9% | IOVA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.